Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toujeo versus standard basal insulin in uncontrolled type 2 diabetes mellitus
NL-OMON43525Phase 4Withdrawn
- Sponsor
- Sanofi
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine, insulin detemir, insulin isophane and insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: HbA1c change from baseline to Month 6. Planned start Feb 2016; status: withdrawn.
02
Drugs
insulin glargineinsulin detemirinsulin isophaneinsulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON43525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43525.